ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) CEO Bill Hearl, Ph.D., will participate in a panel discussion on immunotherapy at the 2018 BioHealth Capital Region Forum. Dr. Hearl will discuss the complex landscape of immune-oncology technologies and Immunomic’s LAMP-Vax™ technology platform. The investigational LAMP-Vax vaccine platform works with the body’s natural biochemistry and has the potential to complement a variety of immuno-modulatory therapies. The Forum is presented by BioHealth Innovation, VirginiaBio, Inova, Children’s National Health System, Qiagen, Maryland Tech Council, and University System of Maryland and MedImmune/AstraZeneca.
Panel participants include:
- Bill Hearl, CEO, Immunomic Therapeutics, Inc.
- Matthew Mulvey, PhD, Founder & CEO, Benevir
- Jeffrey Ulmer, PhD, Head, Preclinical R&D, GSK Vaccines
- John Mumm, PhD, Director, Immunoncology R&D, MedImmune, Moderator
Who: Immunomic Therapeutics, Inc. CEO Bill Hearl, Ph.D.
What: From lab to patient: Driving innovation and entrepreneurship in the BioHealth Capital Region. Panel discussion will focus on BioHealth Regionals Strengths: Immune-Oncology, Cell Therapy & Vaccines.
When: Monday, April 23, 11:30 a.m. – 12:30 p.m. EDT
Where: MedImmune, 1 MedImmune Way, Gaithersburg, Maryland
ITI’s investigational LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put LAMP-Vax technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. LAMP is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of LAMP in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for LAMP-Vax therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the investigational LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and its investigational LAMP Technology, visit www.immunomix.com.